Posted by Michael Wonder on 01 Aug 2023
Global sarcoma therapy now listed on Pharmaceutical Benefits Scheme
31 July 2023 - Yondelis (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine.
Australian cancer patients who have been diagnosed with rare soft tissue sarcomas will now have affordable access to a global therapy shown to improve survival, following its listing on the Pharmaceutical Benefits Scheme.
